SHL is a leading developer and manufacturer of advanced drug delivery systems such as autoinjectors and partner to global pharma and biotech firms.

The company’s products enable effective and precise delivery of highly complex biologics and biosimilar drugs.

SHL was founded in 1989 by Swedish entrepreneur Roger Samuelsson. The company is headquartered in Zug, CH and has operations in Europe, Asia and the US, employing approximately 5,000 people.

To SHL Medical

Market trends and drivers

SHL operates in a highly attractive market with strong double-digit growth and limited cyclicality, driven by the underlying fast growing biologics and biosimilar market. The company holds a leading market position with deep innovation and manufacturing capabilities, proprietary IP, strong track record with global pharmaceutical companies as well as a diversified customer base. The market is characterized by high entry barriers due to protected IP and customers who require a proven track record of suppliers of mission-critical devices.

Investment Potential

EQT, in partnership with the founder and majority shareholder of SHL, Roger Samuelsson, will focus on supporting the company to capture market potential, including successful scaling of marketed drugs and capturing fair market share on new pipeline products through commercial excellence. Furthermore, EQT will help to re-enforce the SHL platform and strengthen corporate functions to adapt to scale, accelerate digitalization and optimize global footprint to offer additional value propositions to customers.

Societal contribution

The icons illustrate the portfolio companies' positive societal contributions based on their solutions i.e. how their products and/or services solve key challenges expressed as the Sustainable Development Goals (SDGs)

Board of Directors

Ulrich Faessler Chairperson
Andreas Aschenbrenner Board member
Steffen Oppenlaender Board member
Petra Rumpf Board member
Stephen Oesterle Board member
Richard Ridinger Board member

Management

Ulrich Faessler CEO